Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
Status:
Completed
Trial end date:
2017-04-27
Target enrollment:
Participant gender:
Summary
The goal of the study is to assess the efficacy and safety of mifepristone 300 or 900-mg
once-daily dosing by mouth for 4 weeks in patients with central serous chorioretinopathy.